| Date | Title | Description |
| 12.02.2025 | Скандал в мире фармы: Cassava Sciences соврала о положительном результате лекарства от Альцгеймера | 3 мая 2021 года Мэтт Прайс отвез своего 73-летнего отца Стивена в Нью-Джерси, чтобы сделать ему первую инъекцию нового экспериментального лекарства «Симуфилама» от компании Cassava Sciences. Препарат, предназначенный для лечения болезни Аль... |
| 25.01.2025 | A Double-Edged Sword: The Erosion of Accountability in American Governance and Business | In recent days, two significant events have unfolded in the United States, casting shadows over the pillars of accountability and transparency. The first involves President Trump’s mass firing of independent inspectors general, a move that ... |
| 25.01.2025 | Pfizer to pay $59.7 million over kickbacks for migraine drug | Pfizer to pay $59.7 million over kickbacks for migraine drug
By Jonathan StempelJanuary 24, 202511:00 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Pfizer company logo is seen at a Pfizer offi... |
| 02.12.2024 | Health | Drug, now in testing, has promise for epileptic seizures | Biohaven Ltd. a Connecticut-based biopharmaceutical company, is working to enroll 390 participants for the second and third phases of a clinical trial designed to determine whether the drug can decrease the average seizure frequency in pati... |
| 21.10.2022 | Biohaven Announces Pricing of Public Offering of Common Shares | NEW HAVEN, Conn., Oct. 20, 2022 /PRNewswire/ -- Biohaven Ltd. BHVN ("Biohaven") announced today the pricing of the public offering of 25,000,000 of its common shares, at a public offering price of $10.50 per common share. Biohaven... |
| 05.08.2022 | Biohaven touts surge in Nurtec sales ahead of Pfizer takeover | Forget buyer’s remorse, Pfizer is likely feeling pretty good about its $11.6 billion Biohaven takeover deal following reports of a 57% sales boost for migraine med Nurtec.
Biohaven reported in Q2 results on Friday that it’... |
| 07.07.2022 | Pharmacists 'ready to get to work' after new FDA authorization allows them to prescribe Pfizer's Covid-19 antiviral | With one migraine drug on the market, Biohaven has gone big with its next phase of growth, targeting major neurodegenerative diseases in Alzheimer’s and ALS. The former effort has already gone up in smoke, and a new failure elsewhere in the... |
| 11.05.2022 | A Y Combinator alum on how the startup hustle came at a steep cost—to her mental health | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
The following essay was contributed by Trisha Bantigue, CEO and co-founder of the San Francisco-b... |
| 14.02.2022 | Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea | NEW HAVEN, Conn. and NEW YORK, Feb. 14, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced positive top-line results from an Asia-Pacific, Phase 3 clinical trial of ri... |
| 25.01.2022 | Biohaven's Nurtec® ODT Extends Partnership with Rick Ware Racing for 2022 NASCAR Cup Series and NTT INDYCAR Series | MOORESVILLE, N.C., Jan. 25, 2022 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec® ODT (rimegepant) extends its sponsorship for the second year as the primary partner for the No. 51 Rick Ware Racing entry dur... |
| 10.01.2022 | Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain | NEW HAVEN, Conn. and LEUVEN, Belgium, Jan. 10, 2022 /PRNewswire/ -- Biohaven Therapeutics Ltd., a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), along with CD3 and LICR at KU Leuven, announced today that they have ... |
| 06.01.2022 | BIOHAVEN ANNOUNCES PRELIMINARY 4Q2021 AND FULL YEAR NET PRODUCT REVENUE FOR NURTEC ODT, MARKET LEADING NOVEL MIGRAINE THERAPY | NEW HAVEN, Conn., Jan. 6, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced preliminary net product rev... |
| 05.01.2022 | Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States | NEW HAVEN, Conn. and NEW YORK, Jan. 5, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced that the parties have completed the collaboration transaction between the two... |
| 13.12.2021 | BIOHAVEN ANNOUNCES NURTEC® ODT RECEIVES FIRST GLOBAL APPROVAL OUTSIDE THE U.S. FOR PREVENTION OF MIGRAINE | NEW HAVEN, Conn., Dec. 13, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today that NURTEC ODT (rimegepant) 75 mg was approved by the Ministry of Health of Israel for the pre... |
| 09.11.2021 | Biohaven Reports Third Quarter 2021 Financial Results And Recent Business Developments | NEW HAVEN, Conn., Nov. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases including ra... |
| 09.11.2021 | Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States | NEW HAVEN, Conn. and NEW YORK, Nov. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced a strategic commercialization arrangement for rimegepant in markets outside o... |
| 09.11.2021 | Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States | NEW HAVEN, Conn. and NEW YORK, Nov. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced a strategic commercialization arrangement for rimegepant in markets outside o... |
| 02.11.2021 | Nine Line Apparel and Biohaven's Nurtec ODT Set to Honor World War II Veterans Ahead of 80th Anniversary at Phoenix Raceway | MOORESVILLE, N.C., Nov. 2, 2021 /PRNewswire/ -- Rick Ware Racing (RWR) has joined forces once again with Nine Line Apparel and Biohaven Pharmaceuticals' Nurtec® ODT (rimegepant) to pay tribute and honor the upcoming 80th Anniversary of the ... |
| 05.10.2021 | Biohaven Pharmaceutical : Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment | NEW HAVEN, Conn., Oct. 5, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candid... |
| 09.08.2021 | Biohaven Pharmaceutical : Reports Second Quarter 2021 Financial Results And Recent Business Developments | NEW HAVEN, Conn., Aug. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases including ra... |
| 29.07.2021 | Biohaven's Nurtec® ODT Signs as Official Migraine Partner of Big Machine Music City Grand Prix Race | |
| 29.07.2021 | Biohaven Pharmaceutical : Nurtec® ODT Signs as Official Migraine Partner of Big Machine Music City Grand Prix Race | NASHVILLE, Tenn., July 29, 2021 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today Nurtec® ODT (rimegepant) is the official migraine partner of the Big Machine Music City Grand Prix. Romain Grosjean of Rick Ware Racing wil... |
| 07.07.2021 | Biohaven Pharmaceutical : Announces Preliminary 2Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment | NEW HAVEN, Conn., July 7, 2021 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candi... |
| 07.07.2021 | Biohaven Announces Preliminary 2Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment | |
| 23.06.2021 | Sosei : Heptares Initiates Phase 1 Trial with Novel Small-Molecule CGRP Antagonist under Collaboration with Biohaven | PRESS RELEASE
Sosei Heptares Initiates Phase 1 Trial with Novel Small- Molecule CGRP Antagonist under Collaboration with Biohaven
First clinical trial with lead candidate HTL0022562 (BHV3100) to be conducted by Sosei Heptares
Candidate disc... |
| 27.05.2021 | FDA Approves Biohaven's NURTEC® ODT (rimegepant) for Prevention: Now the First and Only Migraine Medication for both Acute and Preventive Treatment | |
| 27.05.2021 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
FDA Approves Biohaven's NURTEC® ODT (rimegepant) for Prevention: Now the First and Only Migraine Medication for both Acute and Preventive Treatment | NEW HAVEN, Conn., May 27, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that the U.S. Food and Drug Administration (FDA) has approved NURTEC® ODT (rimegepant 75 mg) for the preventive treatm... |
| 14.05.2021 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
Biohaven Pharmaceutical : Nurtec® ODT Signs as Primary Partner with Rick Ware Racing for 2021 NTT INDYCAR Series Program | MOORESVILLE, N.C., May 14, 2021 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec® ODT (rimegepant) will be the primary partner for the Rick Ware Racing No. 51 NTT IndyCar Series program. Nurtec ODT's vibrant ... |
| 14.05.2021 | Biohaven's Nurtec® ODT Signs as Primary Partner with Rick Ware Racing for 2021 NTT INDYCAR Series Program | |
| 10.05.2021 | Biohaven Pharmaceutical : C O R R E C T I O N -- Biohaven Pharmaceutical Holding Company Ltd./ | As a result of an inadvertent error, the version of the earnings release Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven") issued before market open on May 10, 2021 (the "Original Earnings Release") included cert... |
| 07.04.2021 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
Biohaven Pharmaceutical : Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT | NEW HAVEN, Conn., April 7, 2021 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product cand... |
| 06.04.2021 | Rick Ware Racing, Biohaven's Nurtec ODT and Nine Line Apparel Honor Fallen Service Members | |
| 06.04.2021 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
Biohaven Pharmaceutical : Rick Ware Racing, Biohaven's Nurtec ODT and Nine Line Apparel Honor Fallen Service Members | MOORESVILLE, N.C., April 6, 2021 /PRNewswire/ -- Rick Ware Racing announced today its partnership with Biohaven's Nurtec® ODT (rimegepant) and Nine Line Apparel to honor the nation's fallen service members during the Memorial Day weekend Co... |
| 15.03.2021 | Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares | |
| 15.03.2021 | Biohaven Announces Proposed Public Offering Of Common Shares | |
| 25.01.2021 | Biohaven Announces Preliminary 4Q2020 Net Product Revenue For NURTEC® ODT | |
| 18.01.2021 | Biohaven Signs Cody Ware as Driver for Nurtec® ODT Chevrolet for the 2021 NASCAR Cup Series Season | |
| 07.01.2021 | Biohaven Pharmaceutical : Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Labs | NEW HAVEN, Conn., Jan. 7, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") today announced the acquisition of the remaining 58% interest of Kleo Pharmaceuticals,... |
| 05.01.2021 | AbbVie bails on Sosei Heptares pact for novel neurology candidates in blow to discovery outfit's A-list Rolodex | Japan’s Sosei Heptares has built a who’s who list of big-name partners looking to license the companies’ discovery-stage G protein-coupled receptors for novel neurology pathways and beyond. But with Sosei’s goal of sign... |
| 02.12.2020 | Biohaven's Nurtec™ ODT Partners with the Rick Ware Racing Team in the 2021 NASCAR Cup Series | |
| 09.11.2020 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
Biohaven Pharmaceutical : Reports Third Quarter 2020 Financial Results and Recent Business Developments | NEW HAVEN, Conn., Nov. 9, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurologi... |
| 09.11.2020 | Biohaven Pharmaceutical : Reports Third Quarter 2020 Financial Results and Recent Business Developments | NEW HAVEN, Conn., Nov. 9, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurologi... |
| 28.09.2020 | BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region | |
| 28.09.2020 | BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A | Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that BioShin Limited its Asia-Pacific Subsidiary, has closed a $60M Series A investment round. The financing was led by OrbiMed, with participation from Cormorant Ass... |
| 10.09.2020 | Biohaven's Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human Dosing | |
| 19.06.2020 | Boehringer Ingelheim nabs new US president and CEO; AstraZeneca vet hops aboard Novavax as CMO | Jean-Michel Boers
→ Jean-Michel Boers, who joined Boehringer Ingelheim in 1998, is stepping in as US president and CEO. He succeeds Wolfgang Baiker, who is retiring after 31 years with the company. After starting out at Boehr... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| 06.12.2019 | Antibiotic developer scores $50M from biotech billionaire; Biohaven's Alzheimer's drug passes futility test | → Antibiotic developer Summit Therapeutics has scored a cool $50 million in funding from biotech billionaire Robert Duggan — the former chief of Pharmacyclics, the company behind Imbruvica that was sold to AbbVie f... |
| 27.05.2019 | NYSE changes fee schedule in bid to woo biotech companies | “We are providing an improved on-ramp for biotech companies looking to access the public markets and receive the benefits of an NYSE listing, while preserving capital to invest in their businesses,” NYSE COO John Tuttle wrote in an emailed ... |
| 05.05.2017 | Term Sheet — Friday, May 5 | CRYPTO-SPLAINING
Last week a very confusing press release crossed my radar. It read: “The Argon Group is working on the first secondary market raise by ICO. The company, Storj had one of the most successful ICOs several years ago, returning... |
| 25.04.2017 | Term Sheet — Tuesday, April 25 | MONEY-LOSING HOUSE OF HORRORS
Contrarian: The message around Cloudera’s IPO, which is expected to price on Thursday after the market closes, has been yikes. The company was last valued at $4.1 billion; its share pricing values the company a... |
| 07.03.2017 | Biohaven Closes Second Tranche of $80M Private Placement | Biohaven Pharmaceutical Holding Company Ltd., a privately-held, clinical stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, announced toda... |
| 02.11.2016 | Term Sheet — Wednesday, November 1 | Et cetera
Money in the Bank: Yesterday’s Term Sheet included a last-minute deal announcement that deserves a little extra attention today: Battery Ventures, Andreessen Horowitz and Ribbit Capital invested $28 million in Cross River Bank.
Pa... |
| 01.11.2016 | Biohaven Pharmaceutical Completes $80M Venture Capital Funding Round | Biohaven Pharmaceutical Holding Company Ltd., a New Haven, CT-based biopharmaceutical company with expertise in late stage clinical development, completed an $80m vc funding.
The round was led by Venrock with participation from RA Capital M... |
| 01.11.2016 | Biohaven Secures $80 Million in Oversubscribed Private Financing to Advance Phase 3 Clinical Trials | NEW HAVEN, Conn., Nov. 1, 2016 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”), a privately-held biopharmaceutical company with particular expertise in late stage clinical development and a portfolio of multiple lat... |
| 01.11.2016 | Venrock Leads $80 Million Private Financing for Biohaven | Biohaven Pharmaceutical Holding Company Ltd., a privately-held biopharmaceutical company with particular expertise in late stage clinical development and a portfolio of multiple late stage assets, announced today the successful completion o... |
| 13.09.2016 | Yale’s David Spiegel inspires another immuno-oncology R&D spinout focused on Antibody Recruiting Molecules | David Spiegel
A year ago, a joint venture between Bristol-Myers Squibb and Allied Minds picked up some immuno-oncology molecules from the lab of Yale’s David Spiegel. Now his work on Antibody Recruiting Molecules — which lu... |
| 01.09.2016 | Kleo Pharmaceuticals Secures Series A Funding | Kleo Pharmaceuticals Inc., a New Haven, CT-based biotechnology company, secured a Series A funding of undisclosed amount.
The round was led by Biohaven Pharmaceutical Holding Company.
The company intends to use the funds to advance the deve... |
| - | NYSE changes fee schedule in bid to woo biotech companies | When biotechnology companies that don’t yet have products on the market look to go public in order to boost their ability to raise money for drug development and commercialization efforts, they typically go to the Nasdaq. But lately, some o... |
| - | Big Pharma will have $500 billion to spend in 2022 and is hungry for M&A. Here are the 10 biotechs analysts say are takeover targets. | Crystal Cox/Business Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Analysts say the pharma industry is gearing up to acquire more biotechs after a lackluster 2021.
Pharma giants... |
| - | Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments | Cash, cash equivalents, marketable securities and restricted cash totaled approximately $287.6 million on March 31, 2024, which excludes the net proceeds of approximately $247.8 million from Biohaven's public offering completed on April 22,... |
